MX2021004296A - Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados. - Google Patents

Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados.

Info

Publication number
MX2021004296A
MX2021004296A MX2021004296A MX2021004296A MX2021004296A MX 2021004296 A MX2021004296 A MX 2021004296A MX 2021004296 A MX2021004296 A MX 2021004296A MX 2021004296 A MX2021004296 A MX 2021004296A MX 2021004296 A MX2021004296 A MX 2021004296A
Authority
MX
Mexico
Prior art keywords
compositions
acetylcholine receptor
nicotinic acetylcholine
conotoxin
peptide antagonist
Prior art date
Application number
MX2021004296A
Other languages
English (en)
Inventor
Robert A Love
Original Assignee
Glo Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glo Pharma Inc filed Critical Glo Pharma Inc
Publication of MX2021004296A publication Critical patent/MX2021004296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Immunology (AREA)

Abstract

La presente invención está relacionada con antagonistas de péptidos novedosos que inhiben el enlace de la acetilcolina al sitio activo del receptor de acetilcolina tipo muscular. Los antagonistas de péptidos de la invención son útiles es composiciones cosméticas que previenen o mejoran la apariencia de las arrugas de la piel o condiciones de la piel relacionadas. La invención además está relacionada con composiciones cosméticas y farmacéuticas que comprenden un antagonista de péptido de la invención, y métodos para su uso.
MX2021004296A 2018-10-16 2019-10-15 Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados. MX2021004296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746398P 2018-10-16 2018-10-16
US201962867128P 2019-06-26 2019-06-26
PCT/US2019/056360 WO2020081583A1 (en) 2018-10-16 2019-10-15 Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods

Publications (1)

Publication Number Publication Date
MX2021004296A true MX2021004296A (es) 2021-08-05

Family

ID=70158934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004296A MX2021004296A (es) 2018-10-16 2019-10-15 Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados.

Country Status (12)

Country Link
US (3) US11130782B2 (es)
EP (1) EP3866828A4 (es)
JP (2) JP2022514114A (es)
KR (2) KR20230145516A (es)
CN (1) CN113194977A (es)
AU (1) AU2019361942A1 (es)
BR (1) BR112021007131A2 (es)
CA (1) CA3116315A1 (es)
MA (1) MA53932A (es)
MX (1) MX2021004296A (es)
SG (1) SG11202103791PA (es)
WO (1) WO2020081583A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53932A (fr) 2018-10-16 2021-08-25 Glo Pharma Inc Compositions de conotoxine servant d'antagonistes peptidiques des récepteurs nicotiniques de l'acétylcholine et méthodes associées
MX2022003446A (es) 2019-09-23 2022-07-13 Dds Res Inc Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion.
WO2022204308A1 (en) * 2021-03-24 2022-09-29 Glo Pharma, Inc. Multisome lipid vesicles for delivery of cosmetic agents
WO2023008913A1 (ko) * 2021-07-27 2023-02-02 주식회사 스킨메드 아세틸콜린 수용체 결합 최적화 단축 펩타이드 및 이의 용도
CN117084934B (zh) * 2023-10-20 2024-01-19 深圳市维琪科技股份有限公司 多肽的新用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
JPS615095A (ja) * 1984-06-15 1986-01-10 Ajinomoto Co Inc コノトキシンｍｉ（ｂ）類縁体
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU1114399A (en) 1997-10-24 1999-05-17 Case Western Reserve University Interaction of alpha-conotoxin peptides with neuronal nicotinic acetylcho line receptors
WO2000043409A2 (en) * 1999-01-22 2000-07-27 University Of Utah Research Foundation Alpha-conotoxin peptides
US6797808B1 (en) 1999-01-29 2004-09-28 University Of Utah Research Foundation α-conotoxin peptides
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
AU2001278975A1 (en) * 2000-07-20 2002-02-05 Cognetix, Inc. Alpha-conotoxin peptides
WO2002064740A2 (en) 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
DE502005009544D1 (de) 2004-11-02 2010-06-17 Dsm Ip Assets Bv Neue topisch anwendbare wirkstoffe gegen mimische und alterabedingt falten
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CN102007142A (zh) 2008-02-19 2011-04-06 麦欧赛普特股份有限公司 突触后靶向化学去神经剂及它们的使用方法
CN101745097A (zh) * 2008-12-12 2010-06-23 海南大学 特异阻断乙酰胆碱受体的海南产α-芋螺毒素及其用途
RU2473559C1 (ru) 2011-10-26 2013-01-27 Общество с ограниченной ответственностью "Синейро" Пептид аземиопсин, избирательно взаимодействующий с никотиновыми холинорецепторами мышечного типа и пригодный для использования в качестве мышечного релаксанта в медицине и косметологии
ES2678793T3 (es) * 2012-04-13 2018-08-17 Activen Composición cosmética que comprende un muconopéptido
RU2524428C1 (ru) * 2013-01-21 2014-07-27 Общество с ограниченной ответственностью "Синейро" Пептиды и их производные, взаимодействующие с никотиновым ацетилхолиновым рецептором и пригодные для использования в косметологии против мимических и возрастных морщин
US10328011B2 (en) 2015-12-16 2019-06-25 Dsm Ip Assets B.V. Use of proline containing dipeptides
MA53932A (fr) 2018-10-16 2021-08-25 Glo Pharma Inc Compositions de conotoxine servant d'antagonistes peptidiques des récepteurs nicotiniques de l'acétylcholine et méthodes associées
JP2023523899A (ja) 2020-04-09 2023-06-08 ジーエルオー ファーマ，インク． ニコチン性アセチルコリン受容体活性を阻害するためのペプチド組成物および方法

Also Published As

Publication number Publication date
MA53932A (fr) 2021-08-25
BR112021007131A2 (pt) 2021-08-10
EP3866828A4 (en) 2022-08-31
WO2020081583A1 (en) 2020-04-23
US20220048950A1 (en) 2022-02-17
US20200115414A1 (en) 2020-04-16
JP2023117418A (ja) 2023-08-23
JP2022514114A (ja) 2022-02-09
EP3866828A1 (en) 2021-08-25
US11970552B2 (en) 2024-04-30
CA3116315A1 (en) 2020-04-23
KR20210077724A (ko) 2021-06-25
US11130782B2 (en) 2021-09-28
CN113194977A (zh) 2021-07-30
KR20230145516A (ko) 2023-10-17
AU2019361942A1 (en) 2021-06-03
SG11202103791PA (en) 2021-05-28
US20240199699A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
MX2021004296A (es) Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados.
WO2018083087A3 (en) Binding proteins
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
SA518391170B1 (ar) مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة
WO2017044894A3 (en) Cartilage-homing peptides
WO2015051030A3 (en) Stabilized polypeptides and uses thereof
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2016185481A3 (en) Method of targeting senescent cells
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3712144A4 (en) P2X3 AND / OR P2X2 / 3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
WO2015116856A3 (en) Farnesoid x receptor antagonists
TR201902686T4 (tr) Aurora A kinaz inhibitörü.
MX2021005085A (es) Formulacion de anticuerpo.
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
MX2018010546A (es) Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
SA519410097B1 (ar) P2x7 مشتقات رباعي هيدروكوينولين كمعارضات مستقبل
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
WO2015054649A3 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2017140684A3 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
WO2016111523A3 (ko) HNF4-α 길항제 및 이의 용도
EA202190939A1 (ru) Композиции пептидного антагониста никотинового ацетилхолинового рецептора конотоксина и связанные способы